<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04030546</url>
  </required_header>
  <id_info>
    <org_study_id>ICO</org_study_id>
    <nct_id>NCT04030546</nct_id>
  </id_info>
  <brief_title>Ivabradine to Prevent Anthracycline-induced Cardiotoxicity</brief_title>
  <official_title>Ivabradine to Prevent Anthracycline-induced Cardiotoxicity: a Prospective Randomized Open Label Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vilnius University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vilnius University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate protective effects of ivabradine in adult cancer
      patients undergoing anthracycline-based chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cancer treatment with anthracyclines may cause heart damage and can lead to heart failure.
      There are drugs which may protect against cardiotoxic effects of anthracyclines
      (renin-angiotensin inhibitors and beta blockers), but they are not tolerated due to
      hypotension. Ivabradine is heart rate lowering drug without effect on blood pressure which
      was approved for treatment of angina pectoris and heart failure. The aim of this study is to
      investigate protective effects of ivabradine in cancer patients undergoing
      anthracycline-based chemotherapy.

      Ivabradine selectively inhibits If currents in the sinus node and prolongs the duration of
      spontaneous depolarization. That controls the heart's contractions and regulates the heart
      rate. Additionally, ivabradine might preserve myocardial function and contractility without
      effect on blood pressure. Ivabradine was approved for symptomatic treatment of chronic stable
      angina pectoris and chronic heart failure.

      The aim of this study is to investigate protective effects of ivabradine in adult cancer
      patients undergoing anthracycline-based chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in left venticular dysfunction by global longitudinal strain (GLS).</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>Change in global longitudinal strain (GLS) at least by 3%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of myocardial injury according to levels of high-sensitivity cardiac troponin T and NT-proBNP</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>Incidence of myocardial injury according to levels of high-sensitivity cardiac troponin T and NT-proBNP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of left ventricular systolic and diastolic dysfunction by 2D and 3D echocardiography.</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>Incidence of left ventricular (LV) dysfunction defined as drop of LV ejection fraction by ≥ 10%.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of symptomatic heart failure.</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>Incidence of symptomatic heart failure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in left ventricular and right ventricular dimensions by 2D and 3D echocardiography.</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>Changes in left ventricular and right ventricular dimensions by 2D and 3D echocardiography.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Patients With Cancer</condition>
  <arm_group>
    <arm_group_label>Ivabradine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive ivabradine just before anthracycline chemotherapy, 5 mg per oral twice daily, until the last chemotherapy session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient will receive usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine</intervention_name>
    <description>Ivabradine capsule</description>
    <arm_group_label>Ivabradine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cancer patients undergoing anthracyclines based chemotherapy;

          -  heart rate (HR) &gt; 70 times per minute;

          -  Written informed consent.

        Exclusion Criteria:

          -  Contraindications for ivabradine administration;

          -  HR&lt;70 times per minute;

          -  Incapability to complete informed consent;

          -  Severe valve disease;

          -  Left ventricular ejection fraction (LVEF)≤ 30 %;

          -  Other severe conditions;

          -  Poor echogenicity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sigita Aidietiene, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vilnius University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sigita Aidietiene, MD, PhD</last_name>
    <phone>37052365214</phone>
    <email>sigita.aidietiene@santa.lt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Egle Ciburiene, MD</last_name>
    <phone>37052365214</phone>
    <email>egle.ciburiene@santa.lt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vilnius University Hospital Santaros klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Egle Ciburiene, MD</last_name>
      <email>egle.ciburiene@santa.lt</email>
    </contact>
    <contact_backup>
      <last_name>Sigita Aidietiene, MD, PhD</last_name>
      <email>sigita.aidietiene@santa.lt</email>
    </contact_backup>
    <investigator>
      <last_name>Sigita Aidietiene, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Egle Ciburiene, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jelena Celutkiene, MD, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Lithuania</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>July 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vilnius University</investigator_affiliation>
    <investigator_full_name>Sigita Aidietiene</investigator_full_name>
    <investigator_title>Assoc. Prof.</investigator_title>
  </responsible_party>
  <keyword>anthracycline chemotherapy</keyword>
  <keyword>cardiotoxicity</keyword>
  <keyword>heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

